NCT02607228 2020-12-08Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate CancerGilead SciencesPhase 1/2 Terminated31 enrolled 22 charts